Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).

@article{Monsonego2012RiskAA,
  title={Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).},
  author={Joseph Monsonego and Michael Hudgens and Laurent Zerat and J C Zerat and Kari Juhani Syrj{\"a}nen and Justin S Smith},
  journal={Gynecologic oncology},
  year={2012},
  volume={125 1},
  pages={
          175-80
        }
}
OBJECTIVE New commercial HPV RNA assays require further validation studies in population-based cervical cancer screening settings. To assess the performance of (FDA-approved) APTIMA® HPV Assay (AHPV), Hybrid Capture 2 (HC2), in-house PCR genotyping, and ThinPrep LBC in population-based screening, stratified by three histological gold standards. STUDY DESIGN A multi-center trial in 5006 women undergoing routine screening in France was designed to compare the absolute and relative risks of… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

Similar Papers

Loading similar papers…